Berenberg raises target for Evonik stock from EUR 15.50 to EUR 20.00

Published on 10/13/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock costs EUR 21.25 on October 13, 2026, versus EUR 21.10. Adjusted EBITDA rose 24.00 percent to EUR 630 million in the second quarter.

Berenberg upgraded Evonik to Hold from Sell and raised its price target from EUR 15.50 to EUR 20.00 on October 5, 2026.
Evonik reported adjusted EBITDA of EUR 630 million for the second quarter of 2026, up 24.00 percent year over year.
The stock was trading at EUR 21.25 at Lang & Schwarz on October 13, 2026, 0.71 percent above the Xetra close of October 12, 2026.
Evonik is scheduled to report third-quarter 2026 results on November 3, 2026.

Draufsicht auf Aktienzertifikat, ISIN-Karte DE000EVNK013 und Spezialchemie-Laborutensilien auf Marmor — Evonik Industries DE000EVNK013 als Flatlay mit Aktienzertifikat, ISIN-Karte und Chemielabor-Utensilien auf Marmor, Illustration mit AI erstellt.

Berenberg raised its price target for Evonik stock from EUR 15.50 to EUR 20.00 and upgraded the shares from Sell to Hold on October 5, 2026, according to Investing.com. Evonik stock was trading at EUR 21.25 at Lang & Schwarz on October 13, 2026 at 9:37 a.m. CEST, 0.71 percent above the Xetra close of October 12, 2026 at EUR 21.10.

What the upgrade changes

Berenberg's new target is 5.88 percent below the Lang & Schwarz price, using the target and current price in euros. The analyst said BASF's interest in a potential takeover could provide a floor for Evonik, while weaker methionine prices remain a risk, according to Investing.com.

Second-quarter earnings set the base

Evonik's adjusted EBITDA rose 24.00 percent year over year to EUR 630 million in the second quarter of 2026. Management said higher volumes and higher prices each contributed 7.00 percent to the increase, while Advanced Technologies was a key earnings driver, according to the Yahoo Finance transcript.

Three dated milestones

On July 8, 2026, Evonik announced a USD 100 million investment in pharmaceutical active-ingredient production in Lafayette, Indiana. On August 4, 2026, the company reported its strong second-quarter performance and raised its full-year adjusted EBITDA guidance to EUR 2.0 billion-2.2 billion. On October 5, 2026, Berenberg moved its rating to Hold and raised the target to EUR 20.00, according to Evonik's investor-relations page and Investing.com.

Dates for the next reports

Evonik is scheduled to report third-quarter 2026 results on November 3, 2026, followed by fourth-quarter 2026 reporting on March 4, 2027, according to the company's investor-relations calendar. The dates give the market two defined checkpoints for testing whether the second-quarter improvement is continuing.

Stock stays near its yearly high

Evonik's 52-week range was EUR 12.49 to EUR 21.64 on October 13, 2026, putting the current price 1.80 percent below the high. Market capitalization stood at EUR 9.9 billion on the same date, while the 0.71 percent premium to the Xetra close kept the daily move below the threshold for a directional headline.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.